Unclaimed brand
Coeptis Therapeutics is a clinical stage biotechnology company developing innovative cell therapy platforms for patients with cancer and other debilitating diseases.
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#5897FB
Cornflower Blue
88, 151, 251
217, 95, 66
65, 40, 0, 2
#A7C2E7
Spindle
167, 194, 231
215, 57, 78
28, 16, 0, 9
#002C7D
Resolution Blue
0, 44, 125
219, 100, 25
100, 65, 0, 51
Coeptis Therapeutics, Inc. (OTC PINK: COEP) is a biopharmaceutical company that aims to develop and commercialize generic and branded pharmaceutical products. Founded in 2017 and headquartered in Wexford, PA, Coeptis has evolved into a leading biopharmaceutical company focused on the development of innovative cell therapy platforms.
Through its wholly owned subsidiary, Coeptis Pharmaceuticals, Inc., the company is dedicated to providing advanced therapies for patients with cancer. Led by a management team with a proven track record in acquiring and developing novel therapies, including Chairman, President, and CEO Dave Mehalick, Coeptis is committed to innovation and expertise in the field of biopharmaceuticals. With a strong focus on research and development, Coeptis Therapeutics strives to transform the future of cancer treatment through its innovative cell therapy platforms.
For more information about their innovative science, investment opportunities, or career opportunities, visit their official website
Allogeneic cell therapy
Oncology biopharmaceuticals
Cell therapy platforms
SNAP-CAR
Stem cell expansion
